RESUMEN

Lactation is contraindicated for women with sickle cell anemia receiving hydroxyurea therapy, despite sparse pharmacokinetics data. In 16 women who were lactating volunteers, we documented hydroxyurea transferred into breastmilk with a relative infant dosage of 3.4%, which is below the recommended 5%-10% safety threshold. Breastfeeding should be permitted for women taking daily oral hydroxyurea.

Asunto(s)

Anemia de Células Falciformes/tratamiento farmacológico , Hidroxiurea/farmacocinética , Lactancia/efectos de los fármacos , Leche Humana/metabolismo , Adulto , Anemia de Células Falciformes/metabolismo , Antineoplásicos/farmacocinética , Antidrepanocíticos , Femenino , Humanos , Leche Humana/efectos de los fármacos